Clinical Trials
4 trialsNCT06654050 2026-03-17
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT05582031 2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2 Withdrawn
NCT03786419 2021-05-13
A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma
Health Pharma Professional Research
Phase 2 Withdrawn
NCT01105390 2013-08-02
AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 2 Withdrawn